{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:15Z","timestamp":1788379815930,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.clinthera.2012.05.010","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T18:19:32Z","timestamp":1340129972000},"page":"1625-1635","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01356017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01356043","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yook-Hwan","family":"Noh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Youn","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Joon","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonglae","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.05.010_bib1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/HJH.0b013e3282f76481","article-title":"Pleiotropic effects of telmisartan: still more to come?","volume":"26","author":"Benndorf","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2012.05.010_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","article-title":"Telmisartan: a review of its use in the management of hypertension","volume":"66","author":"Battershill","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.05.010_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00004872-199917020-00015","article-title":"Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension","volume":"17","author":"Karlberg","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2012.05.010_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00045391-199905000-00007","article-title":"Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension","volume":"6","author":"Neutel","year":"1999","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2012.05.010_bib5","series-title":"Pharmacotherapy\u2014A Pathophysiologic Approach","author":"Dipiro","year":"2011"},{"key":"10.1016\/j.clinthera.2012.05.010_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.05.010_bib7","first-page":"89","article-title":"Telmisartan (micardis)\u2014an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?","volume":"75","author":"Chazova","year":"2003","journal-title":"Ter Arkh"},{"key":"10.1016\/j.clinthera.2012.05.010_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2165\/00003495-199550030-00009","article-title":"Amlodipine","volume":"50","author":"Haria","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.05.010_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(00)02047-X","article-title":"Chiral switches","volume":"355","author":"Tucker","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.05.010_bib12","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1021\/jm00096a005","article-title":"Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction","volume":"35","author":"Goldmann","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2012.05.010_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00005344-200202000-00007","article-title":"Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine","volume":"39","author":"Zhang","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-022X(02)00124-0","article-title":"The importance of stereoselective determination of drugs in the clinical laboratory","volume":"54","author":"Rentsch","year":"2002","journal-title":"J Biochem Biophys Methods"},{"key":"10.1016\/j.clinthera.2012.05.010_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-4347(97)00394-0","article-title":"Pharmacokinetic behaviour of R-(+)- and S-(\u2212)-amlodipine after single enantiomer administration","volume":"703","author":"Luksa","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2012.05.010_bib16","first-page":"187","article-title":"Chiral molecules in hypertension: focus on S-amlodipine","volume":"52","author":"Adik-Pathak","year":"2004","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.clinthera.2012.05.010_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0165-022X(02)00133-1","article-title":"Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry","volume":"54","author":"Streel","year":"2002","journal-title":"J Biochem Biophys Methods"},{"key":"10.1016\/j.clinthera.2012.05.010_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2012.05.010_bib19","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.05.010_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11538850-000000000-00000","article-title":"The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies","volume":"10","author":"Chrysant","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.05.010_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11538440-000000000-00000","article-title":"Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine\/valsartan","volume":"30","author":"da Silva","year":"2010","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2012.05.010_bib22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/hr.2009.133","article-title":"Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension","volume":"32","author":"Ishimitsu","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2012.05.010_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11606-008-0544-x","article-title":"Impact of fixed-dose combination drugs on adherence to prescription medications","volume":"23","author":"Pan","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2012.05.010_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3810\/pgm.2011.11.2495","article-title":"Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension","volume":"123","author":"Guthrie","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2012.05.010_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17425255.2010.494597","article-title":"Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties","volume":"6","author":"Deppe","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clinthera.2010.01.017","volume":"32","author":"Kim","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.05.010_bib29","year":"2003","journal-title":"Guidance for Industry, Bioanalytical Method Validation"},{"key":"10.1016\/j.clinthera.2012.05.010_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jchromb.2005.09.021","article-title":"Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry","volume":"828","author":"Li","year":"2005","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.clinthera.2012.05.010_bib31","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2006.11.008","article-title":"Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study","volume":"28","author":"Park","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.05.010_bib32","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland","year":"2011"},{"key":"10.1016\/j.clinthera.2012.05.010_bib33","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications","author":"Gabrielsson","year":"2007"},{"key":"10.1016\/j.clinthera.2012.05.010_bib34","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","year":"2009"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.05.010_bib35","first-page":"S51","article-title":"Sample size determination for bioequivalence assessment by means of confidence intervals","volume":"30","author":"Diletti","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib36","series-title":"Applied Linear Statistical Models","author":"Kutner","year":"2005"},{"key":"10.1016\/j.clinthera.2012.05.010_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2005.11.007","article-title":"Drug interactions and smoking: raising awareness for acute and critical care providers","volume":"18","author":"Kroon","year":"2006","journal-title":"Crit Care Nurs Clin North Am"},{"key":"10.1016\/j.clinthera.2012.05.010_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002018-200427050-00005","article-title":"Safety of telmisartan in patients with arterial hypertension: an open-label observational study","volume":"27","author":"Michel","year":"2004","journal-title":"Drug Saf"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2012.05.010_bib39","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00005344-199117041-00010","article-title":"Safety profile of lacidipine: a review of clinical data","volume":"17","author":"Endersby","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib40","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/009127000004001206","article-title":"Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1472-8206.2009.00720.x","article-title":"Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects","volume":"23","author":"Bolbrinker","year":"2009","journal-title":"Fundamental Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.05.010_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"Philipp","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.05.010_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1751-7176.2009.00098.x","article-title":"Results of treatment with telmisartan-amlodipine in hypertensive patients","volume":"11","author":"Littlejohn","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T19:57:24Z","timestamp":1687550244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0149291812003608"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.05.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}